ORAMED PHARMACEUTICALS INC
For the period ended Dec 31, 2023. Filed Mar 6, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 6, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
ITEM 16. FORM 10-K SUMMARY
None.
SIGNATURES
Pursuant to the requirements of Section 13 or 15 (d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
ORAMED PHARMACEUTICALS INC.
/s/ Nadav Kidron
Nadav Kidron,
President and Chief Executive Officer
Date: March 6, 2024
Pursuant to the requirements of the Securities and Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| /s/ Nadav Kidron | March 6, 2024 |
|---|---|
| Nadav Kidron, | |
| President and Chief Executive Officer and Director | |
| (principal executive officer) | |
| /s/ David Silberman | March 6, 2024 |
| David Silberman, | |
| Chief Financial Officer | |
| (principal financial and accounting officer) | |
| /s/ Daniel Aghion | March 6, 2024 |
| Daniel Aghion, | |
| Director | |
| /s/ Miriam Kidron | March 6, 2024 |
| Miriam Kidron, | |
| Director | |
| /s/ Arie Mayer | March 6, 2024 |
| Arie Mayer, | |
| Director | |
| /s/ Leonard Sank | March 6, 2024 |
| Leonard Sank, | |
| Director | |
| /s/ Benjamin Shapiro | March 6, 2024 |
| Benjamin Shapiro, | |
| Director | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.